reports
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales...
Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoi...
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results a...
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-...
Athenex Announces a Reverse Stock Split
Athenex Announces a Reverse Stock Split BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholder...
Athenex Announces MHRA Decision on Oral Paclitaxel
Athenex Announces MHRA Decision on Oral Paclitaxel MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study and no major clinical efficacy or safety concerns were expressed BUFFALO, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for...
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positi...
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroup BUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions announced that collaborators at the...
Athenex Exits 503B Sterile Compounding Business
Athenex Exits 503B Sterile Compounding Business Full-year 2022 product sales guidance maintained at 20-25% growth year-over-year BUFFALO, N.Y., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the exit of its 503B sterile compounding business. 503B product sales accounted for approximately 19% of Athenex’s total product sales in the third quarter of 2022. The Company will continue to focus...
Athenex Announces Positive Results of Special Stockholder Meeting
Athenex Announces Positive Results of Special Stockholder Meeting Shareholders voted in favor of all three proposals submitted before the Special Stockholder Meeting BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the results of its special meeting of stockholders (the “Special Meeting”), held as a virtual meeting on November 22, 2022. Athenex shareholders have approved all...
Athenex Announces Closing of the Sale of its China API Business
Athenex Announces Closing of the Sale of its China API Business BUFFALO, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the closing of the sale of its equity interests in its China subsidiaries, which primarily represent the Company’s ownership of its active pharmaceutical ingredient (API) manufacturing business in China, to Chongqing Comfort Pharmaceutical Inc. (Chongqing Comfort). ...
Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Confe...
Athenex to Participate in the 5th Annual Evercore ISI HealthCONx Conference BUFFALO, N.Y., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in the 5th Annual Evercore ISI HealthCONx Conference, taking place virtually November 29 to December 1, 2022. Dr. Johnson Lau, Chief Executive Officer of Athenex, and Dr. Dan Lang, President of Athenex Cell Therapy, will be par...
Athenex Announces Receipt of Positive Nasdaq Listing Determination
Athenex Announces Receipt of Positive Nasdaq Listing Determination Nasdaq Hearing Panel grants continued listing of Athenex and extension to regain compliance with the minimum bid price requirement BUFFALO, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that a Nasdaq Hearings Panel has granted the company's request for continued listing on The Nasdaq Stock Market, subject to the C...
Athenex Provides Third Quarter 2022 Financial Results and Business Upd...
Athenex Provides Third Quarter 2022 Financial Results and Business Update Bolstered balance sheet with $30 million public offering of common stock and warrantsNasdaq Hearing Panel grants Athenex’s request for continued listingAthenex is in the final stages of closing the sale of the China API operationsI-SPY 2 study with Oral Paclitaxel expected to be completed by year-end 2022Phase 1 study updates for autologous KUR-501 (GD2 CAR-NKT cell therapy) in relapsed/refractory high-risk neuroblastoma (GINAKIT2) and allogeneic KUR-502 (CD19 CAR-NKT cell therapy) in relapsed/refractory B-cell malign...
Athenex to Provide Corporate and Financial Update for the Third Quarte...
Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022 BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the third quarter 2022 on Thursday, November 3, 2022, before the market opens. Athenex’s management team will host a conference call and live audio webcast at 8:00 a.m. East...
Athenex Files Definitive Proxy Statement for Special Stockholder Meeti...
Athenex Files Definitive Proxy Statement for Special Stockholder Meeting Special Stockholder Meeting will be held as a virtual meeting on November 22, 2022 at 9:30 a.m. Eastern Time BUFFALO, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has filed a definitive proxy statement with the Securities and Exchange Commission in connection with a special meeting of stockholders (th...
Athenex to Participate in the H.C. Wainwright 24th Annual Global Inves...
Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference BUFFALO, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will present at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12-14, 2022, in New York, NY and virtually. Company management will also be available for one-on-one investor meetings during the e...
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Comm...
Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants BUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the pricing of its underwritten public offering of 35,333,334 shares of its common stock and accompanying warrants to purchase up to 35,333,334 shares of common stock at a combined public offering price of $0.75 per share and a...
Athenex, Inc. Announces Proposed Underwritten Public Offering of Commo...
Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants BUFFALO, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock, or pre-funded warrants to purchase common stock in lieu of common stock to certain investors, and accompanying warrants to purchase sha...
Athenex Provides Second Quarter 2022 Financial Results and Business Up...
Athenex Provides Second Quarter 2022 Financial Results and Business Update Reports 2Q product sales of $25.8 million, up 26% year-over-yearRaised $85 million in total transaction value in 2Q for total of $125 million in proceeds from sales of non-core assets in 1H 2022, and reduced Senior Credit Facility balance from $150 million to $57.5 millionCash used in operating activities for 1H 2022 was reduced 42% over the prior yearPresented promising early Phase 1 clinical trial data for CD19 and GD2 CAR-NKT cell products at ASTCT/CIBMTR Tandem Meetings and ASGCT annual meeting in 2Q 2022, respec...
Athenex Announces Publication of Data from Phase 3 Study Comparing Ora...
Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients with Metastatic Breast Cancer in the Journal of Clinical Oncology BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the publication of their manuscript, “Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus E...
Athenex to Provide Corporate and Financial Update for the Second Quart...
Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022 BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the Company will provide a corporate and financial update for the second quarter 2022 on Thursday, July 28, 2022, before the market opens. Athenex’s management team will host a conference call and live audio webcast at 8:00 a.m. Eastern ...
Athenex Announces Entry into Agreement to Sell its China API Business ...
Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd. Expected sale proceeds of approximately $19.0 millionCompany continues to monetize non-core assets to extend cash runwayProceeds from the deal will be used to pay down debt and fund operations BUFFALO, N.Y., July 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that Athenex and certain a...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.